BG103884A - Фармацевтични състави на пептиди, притежаващи малка разтворимост във физиологична среда - Google Patents
Фармацевтични състави на пептиди, притежаващи малка разтворимост във физиологична средаInfo
- Publication number
- BG103884A BG103884A BG103884A BG10388499A BG103884A BG 103884 A BG103884 A BG 103884A BG 103884 A BG103884 A BG 103884A BG 10388499 A BG10388499 A BG 10388499A BG 103884 A BG103884 A BG 103884A
- Authority
- BG
- Bulgaria
- Prior art keywords
- acid
- nonionogenous
- pharmaceutical compositions
- peptide
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- PETRWTHZSKVLRE-UHFFFAOYSA-N 2-Methoxy-4-methylphenol Chemical compound COC1=CC(C)=CC=C1O PETRWTHZSKVLRE-UHFFFAOYSA-N 0.000 abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- 230000003165 hydrotropic effect Effects 0.000 abstract 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract 2
- -1 thyrosine Chemical compound 0.000 abstract 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 abstract 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 235000010233 benzoic acid Nutrition 0.000 abstract 1
- 229960004365 benzoic acid Drugs 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229960005219 gentisic acid Drugs 0.000 abstract 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002885 histidine Drugs 0.000 abstract 1
- 235000001968 nicotinic acid Nutrition 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 abstract 1
- 239000002504 physiological saline solution Substances 0.000 abstract 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 abstract 1
- 229960004889 salicylic acid Drugs 0.000 abstract 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 abstract 1
- 229960004799 tryptophan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретението се отнася до фармацевтични състави,включващи: а) пептид, слабо разтворим във воден физиологичен солев разтвор, като активна съставка; б) нейоногенно хидротропно фармацевтично приемливосредство и в) физиологичен воден разтвор, в койтопептидът (а) е LHRH аналог или GRF пептид и нейоногенното ароматно хидротропно средство (б) е подбрано от никотинамид, никотинова киселина, бензоенакиселина, салицилова киселина, гентизинова киселина, аскорбинова киселина, хистидин, триптофан, фенилаланин, тирозин, креозол, фенол, ксантини, пиродоксин, фолиева киселина, захарин, както и до технитенейоногенни производни.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97108593A EP0880968A1 (en) | 1997-05-28 | 1997-05-28 | Pharmaceutical compositions of peptides having low solubility in physiological medium |
| EP97121246A EP0880969A1 (en) | 1997-05-28 | 1997-12-03 | Pharmaceutical compositions of peptides having low solubility in physiological medium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG103884A true BG103884A (bg) | 2000-07-31 |
| BG64668B1 BG64668B1 (bg) | 2005-11-30 |
Family
ID=26145485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG103884A BG64668B1 (bg) | 1997-05-28 | 1999-11-15 | Фармацевтични състави на пептиди, притежаващи малка разтворимост във физиологична среда |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6331520B1 (bg) |
| EP (2) | EP0880969A1 (bg) |
| JP (1) | JP2002502384A (bg) |
| KR (1) | KR100552546B1 (bg) |
| CN (1) | CN1159062C (bg) |
| AR (1) | AR012868A1 (bg) |
| AT (1) | ATE252909T1 (bg) |
| AU (1) | AU743152B2 (bg) |
| BG (1) | BG64668B1 (bg) |
| BR (1) | BR9809708A (bg) |
| CA (1) | CA2291765A1 (bg) |
| CZ (1) | CZ298825B6 (bg) |
| DE (1) | DE69819322T2 (bg) |
| DK (1) | DK0984788T3 (bg) |
| EA (1) | EA002227B1 (bg) |
| EE (1) | EE04001B1 (bg) |
| ES (1) | ES2210772T3 (bg) |
| HK (1) | HK1029928A1 (bg) |
| IL (2) | IL133176A0 (bg) |
| NO (1) | NO323697B1 (bg) |
| NZ (1) | NZ500777A (bg) |
| PL (1) | PL192647B1 (bg) |
| PT (1) | PT984788E (bg) |
| SI (1) | SI0984788T1 (bg) |
| SK (1) | SK284640B6 (bg) |
| TR (1) | TR199902865T2 (bg) |
| WO (1) | WO1998053844A1 (bg) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8343186B2 (en) | 2004-04-06 | 2013-01-01 | Arthrex, Inc. | Fully threaded suture anchor with transverse anchor pin |
| EP1064934A1 (en) | 1999-06-30 | 2001-01-03 | Applied Research Systems ARS Holding N.V. | GRF-containing lyophilized pharmaceutical composition |
| CA2380423A1 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
| US20040229334A1 (en) * | 2003-05-15 | 2004-11-18 | Mendoza Christine B. | Process for manufacture of nematode-extracted anticoagulant protein (NAP) |
| EP2142207A4 (en) * | 2007-04-04 | 2013-01-16 | Theratechnologies Inc | PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES |
| US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
| US9023826B2 (en) | 2012-10-12 | 2015-05-05 | L'oreal S.A. | Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use |
| US9018177B2 (en) | 2012-10-12 | 2015-04-28 | L'oreal S.A. | Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C |
| JP6295261B2 (ja) * | 2012-10-12 | 2018-03-14 | ロレアル | 少なくとも一種のヒドロトロープ及び少なくとも一種の活性化合物を含む化粧品組成物 |
| US9107853B2 (en) | 2012-10-12 | 2015-08-18 | L'oreal S.A. | Compositions containing phenolic compounds and hydrotropes for cosmetic use |
| US9072919B2 (en) | 2012-10-12 | 2015-07-07 | L'oreal S.A. | Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid |
| US9669242B2 (en) | 2013-07-01 | 2017-06-06 | L'oreal | Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use |
| JP6634758B2 (ja) * | 2015-09-25 | 2020-01-22 | ニプロ株式会社 | 液体組成物及び凍結乾燥製剤 |
| RU2736590C2 (ru) | 2016-02-16 | 2020-11-18 | Стронгбридж Даблин Лимитед | Велдореотид, обладающий плохой растворимостью в физиологических условиях, для применения при лечении акромегалии, акромегалии со злокачественным новообразованием, экспрессирующих sst-r5 опухолей, диабета 2 типа, гипергликемии и опухолей, связанных с гормонами |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4563352A (en) * | 1982-10-04 | 1986-01-07 | The Salk Institute For Biological Studies | Human pancreatic GRF |
| US4935491A (en) * | 1987-08-24 | 1990-06-19 | Board Of Regents, The University Of Texas System | Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine |
| EP0374120A3 (en) * | 1988-12-13 | 1991-07-31 | Monsanto Company | Comosition for controlled release of polypeptides |
| WO1991009617A1 (en) * | 1989-12-21 | 1991-07-11 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
| CA2070061C (en) * | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
| US5487898A (en) * | 1991-08-26 | 1996-01-30 | Abbott Laboratories | Compositions and method for the sublingual or buccal administration therapeutic agents |
| JPH06510046A (ja) * | 1991-08-26 | 1994-11-10 | アボツト・ラボラトリーズ | 治療薬の舌下または頬投与のための組成物及び方法 |
| US5446025A (en) * | 1992-06-12 | 1995-08-29 | Abbott Laboratories | Formulations and method of the percutaneous administration of leuprolide |
| JP2944419B2 (ja) * | 1993-05-10 | 1999-09-06 | ノバルティス アクチエンゲゼルシャフト | 持続性遊離組成物中の薬理学的活性成分の安定 |
| TW280770B (bg) * | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
| AU3562195A (en) * | 1994-10-04 | 1996-04-26 | Novo Nordisk A/S | Preparations containing aspb28 human insulin and nicotinamide |
| KR100236393B1 (ko) * | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
-
1997
- 1997-12-03 EP EP97121246A patent/EP0880969A1/en not_active Withdrawn
-
1998
- 1998-05-26 KR KR1019997010204A patent/KR100552546B1/ko not_active IP Right Cessation
- 1998-05-26 CZ CZ0423199A patent/CZ298825B6/cs not_active IP Right Cessation
- 1998-05-26 ES ES98930729T patent/ES2210772T3/es not_active Expired - Lifetime
- 1998-05-26 AT AT98930729T patent/ATE252909T1/de not_active IP Right Cessation
- 1998-05-26 JP JP50021999A patent/JP2002502384A/ja not_active Withdrawn
- 1998-05-26 IL IL13317698A patent/IL133176A0/xx not_active IP Right Cessation
- 1998-05-26 EA EA199901089A patent/EA002227B1/ru not_active IP Right Cessation
- 1998-05-26 DE DE69819322T patent/DE69819322T2/de not_active Expired - Fee Related
- 1998-05-26 EP EP98930729A patent/EP0984788B1/en not_active Expired - Lifetime
- 1998-05-26 CN CNB988054671A patent/CN1159062C/zh not_active Expired - Fee Related
- 1998-05-26 DK DK98930729T patent/DK0984788T3/da active
- 1998-05-26 EE EEP199900545A patent/EE04001B1/xx not_active IP Right Cessation
- 1998-05-26 WO PCT/EP1998/003079 patent/WO1998053844A1/en active IP Right Grant
- 1998-05-26 AU AU81062/98A patent/AU743152B2/en not_active Ceased
- 1998-05-26 BR BR9809708-3A patent/BR9809708A/pt not_active Application Discontinuation
- 1998-05-26 SK SK1597-99A patent/SK284640B6/sk unknown
- 1998-05-26 CA CA002291765A patent/CA2291765A1/en not_active Abandoned
- 1998-05-26 PT PT98930729T patent/PT984788E/pt unknown
- 1998-05-26 PL PL336982A patent/PL192647B1/pl unknown
- 1998-05-26 NZ NZ500777A patent/NZ500777A/en unknown
- 1998-05-26 SI SI9830555T patent/SI0984788T1/xx unknown
- 1998-05-26 TR TR1999/02865T patent/TR199902865T2/xx unknown
- 1998-05-27 AR ARP980102454A patent/AR012868A1/es active IP Right Grant
-
1999
- 1999-11-15 BG BG103884A patent/BG64668B1/bg unknown
- 1999-11-24 NO NO19995763A patent/NO323697B1/no unknown
- 1999-11-28 IL IL133176A patent/IL133176A/en unknown
- 1999-11-29 US US09/451,013 patent/US6331520B1/en not_active Expired - Fee Related
-
2001
- 2001-02-02 HK HK01100764A patent/HK1029928A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG103884A (bg) | Фармацевтични състави на пептиди, притежаващи малка разтворимост във физиологична среда | |
| MX9709094A (es) | Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina. | |
| MX9601032A (es) | Vehiculos farmaceuticos para nanosuspensiones. | |
| CA2189328A1 (en) | Tocopherol compositions for delivery of biologically active agents | |
| CA2139133A1 (en) | Solid and liquid solutions of drugs which ar not readily soluble in water | |
| PL325825A1 (en) | Microemulsion for use as a carrier for administering active compounds | |
| MY118371A (en) | Tetrahydrolipstatin containing compositions | |
| CA2081068A1 (en) | Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of .alpha.-d-neuraminic acid | |
| KR950703987A (ko) | G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf) | |
| ATE424810T1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| PL337719A1 (en) | Pharmaceutic composition having enhanced anticarcinogenic activity and/or reduced side effects, containing an anticarcinogenic agwent and a derivative of hydroxamic acid | |
| WO2000021510A3 (en) | Formulations of fexofenadine | |
| WO2000045800A3 (en) | Immunosurpressive effects of pteridine derivatives | |
| WO1996024370B1 (en) | Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin | |
| MY137516A (en) | Pharmaceutical composition comprising lumiracoxib | |
| CA2294448A1 (en) | Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins | |
| HUP9901887A2 (hu) | HIV-proteáz inhibitort és vízoldékony E-vitamin származékokat tartalmazó gyógyászati készítmények | |
| AU4949993A (en) | Drugs containing diphosphonic acids and salts thereof | |
| NZ334836A (en) | Liquid alendronate formulations and their use in preventing bone resorption | |
| CA2255064A1 (en) | Potassium, sodium and tris oxaprozin salt pharmaceutical formulations | |
| BG106151A (bg) | Фармацевтичен комплекс | |
| CA2152507A1 (en) | Novel combination of benzoquinazoline antifolates and protecting agents | |
| HUP0002118A2 (hu) | Fiziológiai közegben rosszul oldódó peptideket tartalmazó gyógyszerkészítmények | |
| CA2238920A1 (en) | Nephroprotective pharmaceutical composition and use thereof | |
| CA2223259A1 (en) | Pharmaceutical formulations of highly lipophilic camptothecin derivatives |